可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Mraks AR.Sirolimus for the prevention of in-stent restenosis in a coronary artery[J].N Engl J Med, 2003,349(14):1307-1309.
[2]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.
[3]Cutlip DE,Windecker S,Mehran R,et al.Academic Research Consortium.Clinical end points in coronary stent trials:a case for standardized definitions[J].Circulation,2007,115(17):2344-2351.
[4]Losordo DW,Isner JM,Diaz-Sandoval LJ.Endothelial recovery:thenext target in restenosis prevention[J].Circulation,2003,107(21):2635-2637.
[5]Iijima R,Ikari Y,Amiya E,et al.The impact of metallic allergy on stent implantation:metal allergy and recurrence of in-stent retenosis[J].Int J Cardiol,2005,104(3):319-325.
[6]Dietz U,Dauer C,Lambertz H.Combining short implantation and drug-eluting stenting for routine use yields a low restenosis rate[J].Curr Control Trials Cardiovasc Med,2005,6:18.
[7]赵 惠,肖 虹.冠状动脉洗脱支架的特点及其临床应用[J].中国组织工程研究与临床康复,2009,13(38):7575-7578.
[8]Serruys PW,Regar E,Carter AJ.Rapamycin eluting stent:the onset of a new era in interventional cardiology[J].Heart,2002,87(4):305-307.
[9]倪 钧,沈卫峰,张建盛,等.Firebird药物洗脱支架治疗冠状动脉原发病变[J].介入放射学杂志,2004,13(5):396-398.
[10]杨永祥,王 萍.冠状血管内生物可吸收支架的最新进展[J].中国心血管病研究,2007,5(10):789-791.
[11]王春宇,高润霖,程树林,等.聚-乳酸-乙醇酸涂层冠脉支架的生物相容性实验研究[J].中华心血管病杂志,2003,31(7):528-531.
[12]Mcfadden EP,Stabile E,Regar E,et al. Late thrombosis in drug-eluting coronary after discontinuation of antiplatelet therapy[J].Lancet, 2004,364(9444):1519-1521.